<DOC>
	<DOCNO>NCT02502708</DOCNO>
	<brief_summary>This first-in-children phase 1 trial use indoximod , inhibitor immune `` checkpoint '' pathway indoleamine 2,3-dioxygenase ( IDO ) , combination temozolomide-based therapy treat pediatric brain tumor . Using preclinical glioblastoma model , recently show add IDO-blocking drug temozolomide plus radiation significantly enhance survival drive vigorous , tumordirected inflammatory response . This data provide rationale companion adult phase 1 trial use indoximod ( IND # 120813 ) plus temozolomide treat adult glioblastoma , currently open ( NCT02052648 ) . The goal pediatric study bring IDO-based immunotherapy clinic child brain tumor . This study provide foundation future pediatric trial test indoximod combine radiation temozolomide up-front setting patient newly diagnose central nervous system tumor .</brief_summary>
	<brief_title>Study IDO Pathway Inhibitor , Indoximod , Temozolomide Pediatric Patients With Progressive Primary Malignant Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>Eligibility Criteria Age : 321 year . Group 1 Group 3 : histologically prove initial diagnosis primary malignant brain tumor , exclude brain stem glioma , know curative treatment option . Group 2 : histologically prove initial diagnosis intracranial highgrade glioma ( WHO grade III IV ) , relapse / refractory ependymoma , relapse / refractory medulloblastoma . MRI confirmation ( without gadolinium contrast ) tumor progression regrowth . Surgical debulking permit clinically indicate , follow postoperative repeat MRI . Patients must able swallow whole capsule . Patients metastatic disease eligible enrollment . Patients may corticosteroids management elevate intracranial pressure The dose must stable range decrease least 14 day . Lansky Karnofsky performance status score must &gt; 50 % . Patients must life expectancy 3 month . Creatinine &lt; 1.5times upper limit ageadjusted normal ALT AST &lt; 3times upper limit normal Total bilirubin &lt; 1.5times upper limit normal Absolute neutrophil count ( ANC ) ≥ 750/μL Platelets ≥ 75,000/μL ( transfusion independent ) Hemoglobin ≥ 10 g/dL ( transfusion independent ) Seizure disorder must well control antiepileptic medication . Patients previously treat temozolomide eligible enrollment . Patients must 14 day administration investigational agent prior cytotoxic therapy follow exception : Temozolomide ( allow , regardless time frame administer ) 42 day administration antibodybased therapy ( e.g. , bevacizumab ) . Patients must 9 month initial radiation fraction previously treat conventional fractionated radiation therapy concern pseudoprogression . Patients prior therapy include interstitial brachytherapy , Gliadel wafer , stereotactic radiosurgery must confirmation progressive disease , rather radiation necrosis , PET scanning , Thallium scanning , MRI spectroscopy , surgical documentation . Concurrent antineoplastic therapy : No investigational commercial agent therapy indoximod , temozolomide , and/or conformal radiation therapy may administer intent treat patient 's malignancy remain enrol study . Sexually active female patient childbearing age must agree use two form contraception ( hormonal either barrier method birth control abstinence ) prior study entry duration study participation . Use contraception and/or abstinence continue minimum 1 month completion study . Female patient breastfeed must agree cease breastfeed switch commercially available infant formula appropriate nutrition prior study entry duration study participation , plus minimum 1 month completion study . Sexually active male patient must agree use barrier contraception ( condom ) abstinence prior study entry duration study participation . Use contraception and/or abstinence continue minimum 1 month completion study . Patients and/or parent legal guardian must sign write informed consent treatment clinical study . Exclusion Criteria Patients primary tumor brain stem , include diffuse intrinsic pontine glioma , exclude . Patients swallow whole capsule exclude Prior invasive malignancy , primary central nervous system tumor , unless patient disease free therapy disease minimum 3 year Patients baseline QTc interval 470 msec study entry , patient congenital long QTc syndrome . Active systemic infection require treatment , include HIV infection toxoplasmosis Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study Baseline QTc interval 470 congenital long QT syndrome Active autoimmune disease Pregnant woman exclude study , pregnancy confirm positive serum hCG laboratory test ( &gt; 5 mIU/mL ) ; breastfeed discontinue .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>glioma</keyword>
	<keyword>gliosarcoma</keyword>
	<keyword>malignant brain tumor</keyword>
	<keyword>ependymoma</keyword>
	<keyword>medulloblastoma</keyword>
</DOC>